We have earlier shown that among many pathogenic GNAO1 variants, those losing their PM localization invariably lead to clinical manifestations that include epilepsy, while those that clinically lead to the motor dysfunction‐only phenotypes retain their PM localization [13, 17]. This evidence concerns the gene GNAO1 and epilepsy.